Market Place
Sourcing Support
Bolt Biotherapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics Updates on BDC-4182 & BDC-1001 Data at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics Announces Changes to its Board of Directors
04 Sep 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Participate in Upcoming September Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Q2 2024 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Bolt Bio Reports Q1 2024, Pipeline Prioritization, Leadership Changes
14 May 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at TD Cowen 44th Annual Healthcare Conference
27 Feb 2024 //
GLOBENEWSWIRE
Bolt Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001
05 Dec 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
07 Nov 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Presents Data from Phase 1 Trial of BDC-1001
23 Oct 2023 //
GLOBENEWSWIRE
Bolt to Present Data at the Society for Immunotherapy of Cancer™s 2023 Meeting
18 Oct 2023 //
GLOBENEWSWIRE
Bolt Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients
17 Oct 2023 //
GLOBENEWSWIRE
Bolt to Present New Clinical Data from Completed Phase 1/2 of BDC-1001
16 Oct 2023 //
GLOBENEWSWIRE
Bolt Receives Orphan Drug Designation for BDC-1001 for Gastric Cancers
28 Sep 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering BDC-3042
12 Sep 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Participate in September Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001
03 Aug 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
31 Jul 2023 //
GLOBENEWSWIRE
Bolt Highlights Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001
25 May 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Bolt to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001
26 Apr 2023 //
GLOBENEWSWIRE
Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours
30 Mar 2023 //
CLINICAL TRIALS ARENA
Bolt Announces Positive Data from BDC-1001 PI Trial in HER2-Expressing Tumors
29 Mar 2023 //
GLOBENEWSWIRE
Bolt Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042
14 Mar 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
28 Feb 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at February Investor Conferences
01 Feb 2023 //
GLOBENEWSWIRE
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
14 Dec 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports 3Q 2022 Financial Results & Provides Update
10 Nov 2022 //
GLOBENEWSWIRE
Bolt to Present Preclinical Data on BDC-3042, Dectin-2 Targeting
07 Nov 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
01 Nov 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global
31 Aug 2022 //
GLOBENEWSWIRE
Bolt throws a wrench in the pipeline, looking to conserve cash
13 Aug 2022 //
ENDPTS
Bolt Biotherapeutics Reports Q2 Financial Results and Provides Business Update
10 Aug 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing in Solid Tumors
27 May 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
Bolt Bio to Present Updates for Three PC IO Pipeline Programs at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Bolt Bio Doses First Patient with BDC-1001+OPDIVO in Ongoing Phase 1/2
06 Jan 2022 //
GLOBENEWSWIRE
Bolt`s immune-stimulating antibody conjugate underwhelms in early cancer trial
06 Dec 2021 //
YAHOO
Bolt Bio goes bust as investors boo single response in early test against HER2
06 Dec 2021 //
ENDPTS
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001
02 Dec 2021 //
GLOBENEWSWIRE
Bolt Biotherapeutics Announces Changes to its Board of Directors
19 Nov 2021 //
GLOBENEWSWIRE
Bolt Announces Clinical Collaboration with Bristol Myers to Study BDC-1001
08 Sep 2021 //
BIOSPACE
Innovent and Bolt Biotherapeutics Announce Collaboration
26 Aug 2021 //
PRNEWSWIRE
Bolt Biotherapeutics & Innovent Collaborate to Develop 3 New Oncology Drugs
26 Aug 2021 //
GLOBENEWSWIRE
Bolt Biotherapeutics Announces Closing of Initial Public Offering
09 Feb 2021 //
GLOBENEWSWIRE
Bolt Biotherapeutics strikes a major upsized $230M IPO
06 Feb 2021 //
FIERCE BIOTECH
Solid tumor biotech Bolt Biotherapeutics increases deal size by 29%
04 Feb 2021 //
NASDAQ
Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt
07 Dec 2020 //
PRNEWSWIRE
Bolt Presents BDC-1001 Ongoing Clinical Trial Design and Supportive
10 Nov 2020 //
PRNEWSWIRE
Bolt Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical
10 Nov 2020 //
BIOSPACE
Piramal Announces Integrated Development Program with Bolt Biotherapeutics
29 Jul 2020 //
PRNEWSWIRE
Bolt Biotherapeutics nabs $93.5M to push Provenge inventor`s new idea
01 Jul 2020 //
ENDPTS
Bolt Bio preps clinical trials of immune-stimulating cancer drug
11 Nov 2019 //
FIERCE BIOTECH
